Chinese Journal of Cancerindexed by SCI
《癌症》杂志
BMC

About the cover

pISSN: 1000-467X

eISSN: 1944-446X

CN: 44-1195/R

 

View OnlineFirst Articles

New articles accepted recently

View Current Issue

Volume 35 Issue 4

Browse Past Issues

From January 2002


1 Secular trend analysis of lung cancer incidence in Sihui city, China between 1987 and 2011
     Jin-Lin Du, Xiao Lin, Li-Fang Zhang, Yan-Hua Li, Shang-Hang Xie, Meng-Jie Yang, Jie Guo, Er-Hong Lin, Qing Liu, Ming-Huang Hong, Qi-Hong Huang, Zheng-Er Liao and Su-Mei Cao
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2015-8   Downloaded: 1211
2 Elevated peripheral blood lymphocyte-to-monocyte ratio predicts a favorable prognosis in the patients with metastatic nasopharyngeal carcinoma
     Rou Jiang, Xiu-Yu Cai, Zhong-Han Yang, Yue Yan, Xiong Zou, Ling Guo, Rui Sun, Dong-Hua Luo, Qiu-Yan Chen, Pei-Yu Huang, Yan-Qun Xiang, Xing Lu, Lin Wang, Wei-Xiong Xia, Hai-Qiang Mai and Ming-Yuan Chen
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2015-6   Downloaded: 1412
3 Hepatitis B virus reactivation and hepatitis in diffuse large B-cell lymphoma patients with resolved hepatitis B receiving rituximab-containing chemotherapy: risk factors and survival
     Kai-Lin Chen, Jie Chen, Hui-Lan Rao, Ying Guo, Hui-Qiang Huang, Liang Zhang, Jian-Yong Shao, Tong-Yu Lin, Wen-Qi Jiang, De-Hui Zou, Li-Yang Hu, Michael Lucas Wirian and Qing-Qing Cai
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2015-5   Downloaded: 1228
4 Pharmacogenomics of EGFR-targeted therapies in non-small cell lung cancer: EGFR and beyond
     Christopher Delaney,Samuel Frank and R Stephanie Huang
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2015-4   Downloaded: 1619
5 ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) are not primary resistance factors for cabazitaxel
     Rishil J Kathawala, Yi-Jun Wang, Suneet Shukla, Yun-Kai Zhang, Saeed Alqahtani, Amal Kaddoumi, Suresh V Ambudkar, Charles R Ashby and Zhe-Sheng Chen
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2015-3   Downloaded: 1176
    more recently cited papers...


1 Recent progress in nanotechnology for cancer therapy
     Mu-Fei Tang, Lei Lei, Sheng-Rong Guo, Wen-Lin Huang
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2010-9   Downloaded: 11570
2 Clinical implications of hedgehog signaling pathway inhibitors
     Hailan Liu, Dongsheng Gu, Jingwu Xie
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2011-1   Downloaded: 10840
3 Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression
     Takeo Nakanishi, Douglas D. Ross
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2012-2   Downloaded: 10675
4 Esophageal cancer: diagnosis and management
     Steven H. Lin, Joe Y. Chan
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2010-10   Downloaded: 10110
5 Prognosis of 980 patients with gastric cancer after surgical resection
     Wei Wang, Yuan-Fang Li, Xiao-Wei Sun, Ying-Bo Chen, Wei Li, Da-Zhi Xu, Xuan-Xiang Guan, Chun-Yu Huang, You-Qing Zhan, Zhi-Wei Zhou
     [ Abstract ] [ PDF Full-text ] [ PubMed]   2010-11   Downloaded: 9764



Tumor angiogenesis  

Edited by Francesco Pezzella
and Chao-Nan Qian 

Forming efficient vasculature network, also known as tumor angiogenesis, is a critical hallmark in tumor development. Explorations on its underlying molecular mechanisms have resulted in several novel anti-cancer drugs. However, the modest survival benefits from anti-angiogenic therapy have forced us to revisit our understanding on tumor angiogenesis. In this special issue, world-leading experts have contributed their critical thoughts to reveal alternative tumor angiogenesis approaches and potential treatment targets.

 

Read thematic series > 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  - - - - - - - - - - - - - - - - 

Lung cancer 


Edited by Lin Yan and Wei Zhang  

 

Lung cancer accounts for approximately 21% of worldwide cancer deaths and a staggering 1.6 million new cases are diagnosed every year. In China, lung cancer has become a particularly challenging disease because of air pollution and smoking. This thematic series discusses the proper use of targeted agents in treating lung cancer, reviews the application of biomarkers in clinical management and drug development, and analyzes the unique challenges in developing novel drugs for lung cancer in China.

 

Read thematic series > 



CJC Wechat 微信公众号

CJC触屏版


 

Editorial Manager


CJC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:


CJC is now published by BioMed Central

© Chinese Journal of Cancer

ICP 备案序号:粤ICP备12079158号

Sun Yat-sen University Cancer Center

651 Dongfeng Road East,Guangzhou 510060, P.R.China